Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 7, 2013, Pages 1270-1275

  Koga, Fumitaka ^a   Numao, Noboru ^a   Saito, Kazutaka ^a   Masuda, Hitoshi ^a   Fujii, Yasuhisa ^a   Kawakami, Satoru ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Metastasis; Muscle invasive bladder cancer; Risk factor

Indexed keywords

CISPLATIN;

ADULT; AGED; ARTICLE; BLADDER SURGERY; CANCER SPECIFIC SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CYSTECTOMY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTASIS FREE SURVIVAL; MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; SURVIVAL RATE; SURVIVAL TIME; TRANSURETHRAL RESECTION OF THE BLADDER TUMOR;

CHEMORADIOTHERAPY; METASTASIS; MUSCLE-INVASIVE BLADDER CANCER; RISK FACTOR;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CISPLATIN; CYSTECTOMY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MUSCLE, SMOOTH; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 84884669464     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2012.01.014     Document Type: Article

References (31)

1. Gilbert S.M., Wood D.P., Dunn R.L., et al. Measuring health-related quality of life outcomes in bladder cancer patients using the bladder cancer index (BCI). Cancer 2007, 109:1756-1762.
2. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-Year outcome. J Clin Oncol 2001, 19:89-93.
3. Herr H.W., Bajorin D.F., Scher H.I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: 10-Year outcome. J Clin Oncol 1998, 16:1298-1301.
4. Shelley M.D., Barber J., Wilt T., et al. Surgery versus radiotherapy for muscle invasive bladder cancer. Cochrane Database Syst Rev 2002, CD002079.
5. Hagan M.P., Winter K.A., Kaufman D.S., et al. RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys 2003, 57:665-672.
6. Rödel C., Grabenbauer G.G., Kühn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results. J Clin Oncol 2002, 20:3061-3071.
7. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002, 60:62-67. Discussion: 7-8.
8. Shipley W.U., Prout G.R., Einstein A.B., et al. Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery. JAMA 1987, 258:931-935.
9. Tester W., Porter A., Asbell S., et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993, 25:783-790.
10. Weiss C., Engehausen D.G., Krause F.S., et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007, 68:1072-1080.
11. Dalbagni G., Genega E., Hashibe M., et al. Cystectomy for bladder cancer: A contemporary series. J Urol 2001, 165:1111-1116.
12. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001, 19:666-675.
13. Zietman A.L., Sacco D., Skowronski U., et al. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: Results of a urodynamic and quality of life study on long-term survivors. J Urol 2003, 170:1772-1776.
14. NCCN Clinical Practice Guidelines in Oncology Bladder Cancer Version 2 2011. http://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf.
15. Stenzl A., Cowan N.C., De Santis M., et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009, 55:815-825.
16. Koga F., Kihara K., Fujii Y., et al. Favorable outcomes of patients with clinical stage T3N0M0 bladder cancer treated with induction low-dose chemo-radiotherapy plus partial or radical cystectomy vs. immediate radical cystectomy: A single-institutional retrospective comparative study. BJU Int 2009, 104:189-194.
17. Koga F., Kihara K., Yoshida S., et al. Selective bladder-sparing protocol consisting of induction low-dose chemoradiotherapy plus partial cystectomy with pelvic lymph node dissection against muscle-invasive bladder cancer: Oncological outcomes of the initial 46 patients. BJU Int 2012, 109:860-866.
18. Koga F., Yoshida S., Kawakami S., et al. Low-dose chemoradiotherapy followed by partial or radical cystectomy against muscle-invasive bladder cancer: An intent-to-treat survival analysis. Urology 2008, 72:384-388.
19. Yoshida S., Koga F., Kawakami S., et al. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010, 75:387-391.
20. Classification of malignant tumours 2002, Wiley-Liss, New York. 6th ed. L.H. Sobin, C. Wittekind (Eds.).
21. Koga F., Kihara K., Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009, 29:797-807.
22. Chakravarti A., Winter K., Wu C.L., et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: A report from the radiation therapy Oncology Group. Int J Radiat Oncol Biol Phys 2005, 62:309-317.
23. Izzo J.G., Malhotra U., Wu T.T., et al. Association of activated transcription factor nuclear factor κB with chemoradiation resistance and poor outcome in esophageal carcinoma. J Clin Oncol 2006, 24:748-754.
24. Krüger S., Weitsch G., Büttner H., et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications. Int J Cancer 2002, 102:514-518.
25. Levidou G., Saetta A.A., Korkolopoulou P., et al. Clinical significance of nuclear factor (NF)-κB levels in urothelial carcinoma of the urinary bladder. Virchows Arch 2008, 452:295-304.
26. Tanaka M., Koul D., Davies M.A., et al. MMAC1/PTEN inhibits cell growth and induces chemosensitivity to doxorubicin in human bladder cancer cells. Oncogene 2000, 19:5406-5412.
27. Yamamoto S., Tomita Y., Hoshida Y., et al. Prognostic significance of activated Akt expression in pancreatic ductal adenocarcinoma. Clin Cancer Res 2004, 10:2846-2850.
28. Bristow R.G., Hill R.P. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008, 8:180-192.
29. Martinez-Piñeiro J.A., Gonzalez Martin M., Arocena F., et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995, 153:964-973.
30. Koga F., Yoshida S., Tatokoro M., et al. ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS ONE 2011, 6:e27616.
31. Yoshida S., Koga F., Tatokoro M., et al. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy. Cell Cycle 2011, 10:4291-4299.